ADVFN - Advanced Financial Network.
HOME» NASDAQ » A » AMGN Stock Price » AMGN Stock News

Amgen Inc. Share News

 Amgen Inc. (mm) Stock Price
AMGN Stock Price
 Amgen Inc. (mm) Stock Chart
AMGN Stock Chart
 Amgen Inc. (mm) Stock News
AMGN Stock News
 Amgen Inc. (mm) Company Information
AMGN Company Information
 Amgen Inc. (mm) Stock Trades
AMGN Stock Trades

Bayer To Develop Cancer Treatment With Amgen

FRANKFURT -(Dow Jones)- German chemical and pharmaceutical company Bayer AG (BAYN.XE) said Tuesday it has agreed with Amgen Inc. (AMGN) to develop and commercialize a new antibody for treating cancer. MAIN FACTS: -Financial details of the deal weren't disclosed. -Bayer will collaborate with Amgen at its Munich site from the research phase to the completion of initial clinical trials. -After the initial trials have been completed, Bayer will be responsible for further development and commercialization of the product candidate. -In 2009, Bayer had entered into an agreement with Micromet, Inc. to produce another antibody. -Micromet was acquired by Amgen in early 2012. -Frankfurt Bureau, Dow Jones Newswires; 49-69-29725-500

Stock News for Amgen Inc. (AMGN)
DateTimeHeadline
02/21/201716:00:00Repatha® (Evolocumab) Receives European Commission Approval...
02/14/201718:12:25Automatic Shelf Registration Statement of Securities of Well-known...
02/14/201717:07:24Annual Report (10-k)
02/14/201710:47:10Statement of Ownership (sc 13g)
02/14/201709:00:00Amgen Submits Supplemental Biologics License Application For...
02/13/201716:41:37Amended Statement of Ownership (sc 13g/a)
02/09/201712:01:10Amended Statement of Ownership (sc 13g/a)
02/08/201719:32:00Appeals Court Allows Sanofi, Regeneron to Continue Selling Cholesterol...
02/07/201718:13:00FDA Approves Amgen's Parsabiv™ (Etelcalcetide), First New Treatment I...
02/03/201717:08:12Current Report Filing (8-k)
02/03/201716:04:00Amgen Announces Appointment of Charles M. Holley Jr. to Board...
02/03/201712:59:00Good News for Amgen Is God News for Biotech
02/02/201719:20:00Correction to Amgen Repatha Story
02/02/201718:54:30Statement of Changes in Beneficial Ownership (4)
02/02/201718:48:51Statement of Changes in Beneficial Ownership (4)
02/02/201717:07:00Amgen Sees Positive Results in Repatha Study -- 2nd Update
02/02/201717:02:00Amgen Sees Positive Results in Repatha Study
02/02/201716:56:39Current Report Filing (8-k)
02/02/201716:36:00Amgen's Profit Rises on Improved Margins, Steady Top-line Growth
02/02/201716:20:00Amgen Reports Fourth Quarter And Full Year 2016 Financial Results

Amgen Inc. and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2016 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US